<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00336700</url>
  </required_header>
  <id_info>
    <org_study_id>06-016</org_study_id>
    <nct_id>NCT00336700</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer</brief_title>
  <official_title>A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbert J. Zeh, III MD, FACS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Hypothesis: To estimate time to recurrence in pancreatic cancer patients treated with
      adjuvant erlotinib and gemcitabine. Combination therapy will be given for 4 months followed
      by single agent erlotinib for a total of 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PATIENT POPULATION Resected pancreatic cancer patients (R0 resection) within 10 weeks of
      surgery will be eligible, provided that they meet standard eligibility criteria.

      STUDY DESIGN Phase II, open-label trial of erlotinib and gemcitabine. SAFETY PLAN Safety as
      assessed by CTCAE 3.0 STUDY TREATMENT Erlotinib 150 mg/day x 12 months. (oral) Gemcitabine
      1500 mg/m2 IV over 150 minutes q 2 weeks x 4 months Patients will be monitored with serial CT
      scans for the first 2 years after completion of therapy.

      Clinical Practice: Therapy will be administered as an outpatient. Primary Evaluations: Time
      to recurrence CONCOMITANT THERAPY AND CLINICAL PRACTICE No other anti-cancer therapy will be
      allowed while on study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study published November 2010 and no further work will be done
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence Free Survival (RFS)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>The time interval between day 1, cycle 1, of adjuvant treatment to the first date of radiologic recurrence or death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1-year Recurrence Free Survival (RFS)</measure>
    <time_frame>Up to 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>2-year Recurrence Free Survival (RFS)</measure>
    <time_frame>Up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated 1&amp;2 Year Overall Survival (OS)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Time from from date of first study therapy to to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Expression of Epidermal Growth Factor Receptor (EGFR)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Percentage of participants with expression of epidermal growth factor receptor (EGFR) expression in the resected tumors was assessed by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KRAS Mutational Status</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>KRAS mutation status in resected tumor specimens.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine and Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib (oral) 150 mg/day x 12 months Gemcitabine 1500 mg/m2 IV over 150 minutes q 2 weeks x 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1500mg/m2 IV over 150 min IV q 2 weeks 4 months</description>
    <arm_group_label>Gemcitabine and Erlotinib</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150 mg/d Daily, oral 12 months</description>
    <arm_group_label>Gemcitabine and Erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with potentially resectable pancreatic cancer (including ampullary cancer),
             prior to or after surgery will be accrued to this study.

          -  Patients who sign consent prior to surgery must have appropriate diagnostic imaging
             and be evaluated by one of the surgical co-investigators as having resectable disease,
             and probable pancreatic adenocarcinoma.

          -  Patients, who sign consent after surgery, must have adenocarcinoma of the pancreas
             with negative surgical margins.

          -  Adjuvant therapy should start within 10 weeks of surgery

          -  Age 18 years or older

          -  ECOG performance status of 0 - 1 (see Appendix A)

          -  Ability to take oral medications without difficulty

          -  Adequate bone marrow function as evidenced by an absolute neutrophil content (ANC) &gt;
             1500/mL and platelet count &gt; 100,000/mL

          -  Adequate renal function as evidenced by serum creatinine within institutional limits
             or creatinine clearance &gt; 50 ml/minute if above upper institutional limits (ULN)

          -  Adequate hepatic function as evidenced by ALT and total bilirubin within 2 times ULN.

          -  Provision of written informed consent.

          -  Men and women of childbearing potential must be willing to practice acceptable methods
             of birth control to prevent pregnancy.

        Exclusion Criteria:

          -  Positive margins on post operative surgical specimen or evidence of metastatic disease
             (positive retroperitoneal margin is allowed)

          -  Biliary tree cancers are not allowed (Note: Ampullary cancer allowed).

          -  Known severe hypersensitivity to erlotinib or any of the excipients of these products

          -  Any prior treatment with radiation therapy or chemotherapy or vaccines for pancreatic
             cancer.

          -  Other coexisting malignancies or malignancies diagnosed within the last 3 years, with
             the exception of basal cell carcinoma or squamous cell carcinoma of the skin or
             cervical cancer in situ.

          -  Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital,
             or St. John's Wort. Other agents which inhibit CYP3A4 may be used with caution
             (Appendix B)

          -  Treatment with a non-approved or investigational drug prior to treatment.

          -  Incomplete healing from previous oncologic or other major surgery.

          -  Pregnancy or breast feeding (women of childbearing potential).

          -  As judged by the investigator, any evidence of severe or uncontrolled systemic disease
             (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease).

          -  Evidence of any other significant clinical disorder or laboratory finding that makes
             it undesirable for the subject to participate in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herb Zeh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Cancer Centers Network</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2006</study_first_submitted>
  <study_first_submitted_qc>June 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2006</study_first_posted>
  <results_first_submitted>December 23, 2015</results_first_submitted>
  <results_first_submitted_qc>July 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2016</results_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Herbert J. Zeh, III MD, FACS</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pancreas</keyword>
  <keyword>Cancer</keyword>
  <keyword>Pancreatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gemcitabine (900-1500 mg/m2) + Erlotinib (50-150 mg Daily)</title>
          <description>Patients with adenocarcinoma of the pancreas who adjuvant biweekly fixed-dose rate gemcitabine (1500 mg/m2) and daily erlotinib (150 mg/day) for 4 months followed by maintenance erlotinib (150 mg/day) over 8 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gemcitabine (900-1500 mg/m2) + Erlotinib (50-150 mg Daily)</title>
          <description>Patients with adenocarcinoma of the pancreas who adjuvant biweekly fixed-dose rate gemcitabine (1500 mg/m2) and daily erlotinib (150 mg/day) for 4 months followed by maintenance erlotinib (150 mg/day) over 8 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="34" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recurrence Free Survival (RFS)</title>
        <description>The time interval between day 1, cycle 1, of adjuvant treatment to the first date of radiologic recurrence or death.</description>
        <time_frame>Up to 60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily)</title>
            <description>Patients with adenocarcinoma of the pancreas who adjuvant biweekly fixed-dose rate gemcitabine (1500 mg/m2) and daily erlotinib (150 mg/day) for 4 months followed by maintenance erlotinib (150 mg/day) over 8 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence Free Survival (RFS)</title>
          <description>The time interval between day 1, cycle 1, of adjuvant treatment to the first date of radiologic recurrence or death.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="8.2" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>1-year Recurrence Free Survival (RFS)</title>
        <time_frame>Up to 60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily)</title>
            <description>Patients with adenocarcinoma of the pancreas who adjuvant biweekly fixed-dose rate gemcitabine (1500 mg/m2) and daily erlotinib (150 mg/day) for 4 months followed by maintenance erlotinib (150 mg/day) over 8 months.</description>
          </group>
        </group_list>
        <measure>
          <title>1-year Recurrence Free Survival (RFS)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="35" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>2-year Recurrence Free Survival (RFS)</title>
        <time_frame>Up to 60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily)</title>
            <description>Patients with adenocarcinoma of the pancreas who adjuvant biweekly fixed-dose rate gemcitabine (1500 mg/m2) and daily erlotinib (150 mg/day) for 4 months followed by maintenance erlotinib (150 mg/day) over 8 months.</description>
          </group>
        </group_list>
        <measure>
          <title>2-year Recurrence Free Survival (RFS)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="6" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated 1&amp;2 Year Overall Survival (OS)</title>
        <description>Time from from date of first study therapy to to death from any cause.</description>
        <time_frame>Up to 60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily)</title>
            <description>Patients with adenocarcinoma of the pancreas who adjuvant biweekly fixed-dose rate gemcitabine (1500 mg/m2) and daily erlotinib (150 mg/day) for 4 months followed by maintenance erlotinib (150 mg/day) over 8 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated 1&amp;2 Year Overall Survival (OS)</title>
          <description>Time from from date of first study therapy to to death from any cause.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Estimated 1-year OS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="63" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated 2-year OS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="22" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Expression of Epidermal Growth Factor Receptor (EGFR)</title>
        <description>Percentage of participants with expression of epidermal growth factor receptor (EGFR) expression in the resected tumors was assessed by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC).</description>
        <time_frame>Up to 60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily)</title>
            <description>Patients with adenocarcinoma of the pancreas who adjuvant biweekly fixed-dose rate gemcitabine (1500 mg/m2) and daily erlotinib (150 mg/day) for 4 months followed by maintenance erlotinib (150 mg/day) over 8 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Expression of Epidermal Growth Factor Receptor (EGFR)</title>
          <description>Percentage of participants with expression of epidermal growth factor receptor (EGFR) expression in the resected tumors was assessed by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EGFR FISH - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGFR FISH - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGFR IHC - 1+ (incomplete circumferential)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2+ (complete circumferential)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3+ (complete strong circumferential)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>KRAS Mutational Status</title>
        <description>KRAS mutation status in resected tumor specimens.</description>
        <time_frame>Up to 60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily)</title>
            <description>Patients with adenocarcinoma of the pancreas who adjuvant biweekly fixed-dose rate gemcitabine (1500 mg/m2) and daily erlotinib (150 mg/day) for 4 months followed by maintenance erlotinib (150 mg/day) over 8 months.</description>
          </group>
        </group_list>
        <measure>
          <title>KRAS Mutational Status</title>
          <description>KRAS mutation status in resected tumor specimens.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gemcitabine (900-1500 mg/m^2) + Erlotinib (50-150 mg Daily)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/bone marrow</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy/immunology</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/soft tissue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Ocular/Visual - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic), Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam), Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10^9/L)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint-function</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy), Extraocular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pain, Back</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pain, Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration, Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Mood alteration, Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Rash: dermatitis associated with radiation, Chemoradiation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Herbert Zeh, MD</name_or_title>
      <organization>UPMC CancerCenter</organization>
      <phone>412-692-2852</phone>
      <email>zehxhx@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

